IDIQ contract entitled "vivo study of generic drug products in human subjects".

Ended Indefinite Delivery Contract Awarded Feb 11, 2016 Last action Aug 4, 2020

Contract number: HHSF223201610004I
Awardee: Biopharma Services USA UEI DRLXCANKKNN6
Awarding agency: Food and Drug Administration Department of Health and Human Services
Task orders: 4 $8,514,505 obligated

Award facts

Opportunity: FDASOL1146520 Solicitation number

In Vivo Study of Generic Drug Products in Human Subjects Award Notice · Posted Jul 28, 2015
Combined order value: $8,514,505 Current and potential, with all options
Last date to order 100% complete: May 15, 2021
IDV ceiling 43% used: $20,000,000.00
Award type: Single award
Who can order: Only the awarding agency
NAICS code: 541690 Other Scientific and Technical Consulting Services
PSC: B528 Special Studies/Analysis- Regulatory
Set-aside: No set-aside
Competition: Full and Open Competition · 4 offers Negotiated Proposal / Quote
Pricing: Firm Fixed Price

Award details come from SAM.gov/FPDS.

Task orders

Task order	Ordering agency	Obligated	Awarded
New task order under IDIQ contract HHSF223201610004I entitled, "a randomized, open label, two treatment, four period… 75F40120F19005	Food and Drug Administration	$1,845,195	Mar 10, 2020
New task order under IDIQ contract HHSF223201610004I, entitled "pharmacokinetic (PK) study of opioid drug products… 75F40119F19004	Food and Drug Administration	$2,470,791	Sep 16, 2019
Nasal pharmacokinetic (PK)pharmacodynamic (PD) studies of oral combination products containing opioid agonists and… 75F40118F01002	Food and Drug Administration	$2,877,830	Sep 13, 2018
New task order under HHSF223201610004I to perform a study entitled "evaluation of formulation dependence of drug… HHSF22301001T	Food and Drug Administration	$1,320,689	Sep 8, 2016

Transactions

Action	Obligated	Date
Exercise an Option P00004 · Exercise option year 4 IDIQ contract HHSF223201610004I - n vivo study of generic drug products in human subjects	$0	Aug 4, 2020
Other Administrative Action P00005 · Modification 5 is to correct the modification 4 to correct the option years from 3 to 4.	$0	Aug 4, 2020
Exercise an Option P00003 · Exercise option year 3	$0	Aug 1, 2019
Exercise an Option 2 · Exercise option year 2 - IDIQ contract entitled "vivo study of generic drug products in human subjects".	$0	Sep 25, 2018
Exercise an Option 1 · Exercise option year 1 - IDIQ contract entitled "vivo study of generic drug products in human subjects".	$0	Mar 28, 2017
Original award	$2,500	Feb 11, 2016

Quick answers

Who was awarded contract HHSF223201610004I?

HHSF223201610004I was awarded to Biopharma Services USA by Food and Drug Administration (Department of Health and Human Services) on February 11, 2016.

How much is contract HHSF223201610004I worth?

Orders under HHSF223201610004I have obligated $8,514,505. HHSF223201610004I's own ceiling is $20,000,000.

How many orders have been placed under contract HHSF223201610004I?

4 orders have been placed under HHSF223201610004I, the latest on March 10, 2020.

Who can order from contract HHSF223201610004I?

HHSF223201610004I is a single award indefinite delivery contract. Only the awarding agency can place orders on it.

Was contract HHSF223201610004I competed?

The extent of competition for HHSF223201610004I was full and open competition. The government received 4 offers.

On GovTribe

See this IDV's full record

Every order and transaction
The awardee's other awards and teaming partners
Similar IDVs and recompete opportunities
Ask GovTribe AI about this IDV

Try for free Login